About this Journal Submit a Manuscript Table of Contents
ISRN Vascular Medicine
Volume 2012 (2012), Article ID 710765, 23 pages
http://dx.doi.org/10.5402/2012/710765
Review Article

Targeted Treatments for Restenosis and Vein Graft Disease

Bristol Heart Institute, University of Bristol, 7th Floor, Queens Building, Bristol Royal Infirmary, Bristol BS2 8HW, UK

Received 30 September 2012; Accepted 4 November 2012

Academic Editors: C. Hermenegildo, A. Paolicchi, and B. Tesfamariam

Copyright © 2012 Anita C. Thomas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Cardiovascular diseases (CVDs). Fact sheet No 317, 2011.
  2. J. G. Motwani and E. J. Topol, “Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention,” Circulation, vol. 97, no. 9, pp. 916–931, 1998. View at Scopus
  3. M. R. Bennett, “In-stent stenosis: pathology and implications for the development of drug eluting stents,” Heart, vol. 89, no. 2, pp. 218–224, 2003. View at Scopus
  4. C. Landau, R. A. Lange, and L. D. Hillis, “Percutaneous transluminal coronary angioplasty,” The New England Journal of Medicine, vol. 330, no. 14, pp. 981–993, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Asakura, M. Suzuki, H. Nonogi et al., “Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM),” Journal of Cardiovascular Risk, vol. 5, no. 5-6, pp. 331–334, 1998. View at Scopus
  6. C. E. Hagemeyer and K. Peter, “Ex-vivo thrombolytic gene therapy for vein graft patency: the frontier for development of selective, localised therapeutic approaches,” Thrombosis and Haemostasis, vol. 102, no. 1, pp. 3–4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. C. Chan and S. W. Cheng, “Drug-eluting stents and balloons in peripheral arterial disease: evidence so far,” International Journal of Clinical Practice, vol. 65, no. 6, pp. 664–668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Y. Lee, D. W. Park, Y. H. Kim et al., “Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease,” Journal of the American College of Cardiology, vol. 57, no. 12, pp. 1349–1358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. S. Schwartz, D. R. Holmes, and E. J. Topol, “The restenosis paradigm revisited: an alternative proposal for cellular mechanisms,” Journal of the American College of Cardiology, vol. 20, no. 5, pp. 1284–1293, 1992. View at Scopus
  10. J. Lefkovits and E. J. Topol, “Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention,” Progress in Cardiovascular Diseases, vol. 40, no. 2, pp. 141–158, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Komatsu, M. Ueda, T. Naruko, A. Kojima, and A. E. Becker, “Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses,” Circulation, vol. 98, no. 3, pp. 224–233, 1998. View at Scopus
  12. M. R. Bennett and M. O'Sullivan, “Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy,” Pharmacology and Therapeutics, vol. 91, no. 2, pp. 149–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Steele, J. H. Chesebro, A. W. Stanson, et al., “Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model,” Circulation Research, vol. 57, no. 1, pp. 105–112, 1985. View at Scopus
  14. P. R. Moreno, V. H. Bernardi, J. López-Cuéllar et al., “Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina,” Circulation, vol. 94, no. 12, pp. 3098–3102, 1996. View at Scopus
  15. R. Gallo, A. Padurean, V. Toschi et al., “Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries,” Circulation, vol. 97, no. 6, pp. 581–588, 1998. View at Scopus
  16. I. M. Chung, H. K. Gold, S. M. Schwartz, Y. Ikari, M. A. Reidy, and T. N. Wight, “Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment,” Journal of the American College of Cardiology, vol. 40, no. 12, pp. 2072–2081, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Mehta, S. J. George, J. Y. Jeremy et al., “External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting,” Nature Medicine, vol. 4, no. 2, pp. 235–239, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Bult, “Restenosis: a challenge for pharmacology,” Trends in Pharmacological Sciences, vol. 21, no. 7, pp. 274–279, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. E. R. Edelman and M. J. Karnovsky, “Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis,” Circulation, vol. 89, no. 2, pp. 770–776, 1994. View at Scopus
  20. A. Lafont and D. Faxon, “Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials?” Cardiovascular Research, vol. 39, no. 1, pp. 50–59, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Wilensky, J. F. Tanguay, S. Ito et al., “Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia,” American Heart Journal, vol. 139, no. 6, pp. 1061–1070, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. E. S. Brilakis, C. Lichtenwalter, J. A. de Lemos et al., “A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial,” Journal of the American College of Cardiology, vol. 53, no. 11, pp. 919–928, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. M. Gertz and R. L. Wilensky, “Local drug delivery for treatment of coronary and peripheral artery disease,” Cardiovascular Therapeutics, vol. 29, no. 6, pp. e54–e66, 2011. View at Publisher · View at Google Scholar
  24. G. Nakazawa, E. Ladich, A. V. Finn, and R. Virmani, “Pathophysiology of vascular healing and stent mediated arterial injury,” EuroIntervention, vol. 4, pp. C7–C10, 2008. View at Scopus
  25. X. Flores-Ríos, R. Marzoa-Rivas, J. P. Abugattás-de Torres et al., “Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients,” American Heart Journal, vol. 155, no. 4, pp. 648–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. R. Campbell and J. H. Campbell, “Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis,” Experimental and Molecular Pathology, vol. 42, no. 2, pp. 139–162, 1985. View at Scopus
  27. J. H. Campbell and G. R. Campbell, “Smooth muscle phenotypic modulation—a personal experience,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 8, pp. 1784–1789, 2012. View at Publisher · View at Google Scholar
  28. S. J. George, A. B. Zaltsman, and A. C. Newby, “Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein,” Cardiovascular Research, vol. 33, no. 2, pp. 447–459, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Fitzgerald, I. P. Hayward, A. C. Thomas, G. R. Campbell, and J. H. Campbell, “Matrix metalloproteinases can facilitate the heparanase-induced promotion of phenotypic change in vascular smooth muscle cells,” Atherosclerosis, vol. 145, no. 1, pp. 97–106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. J. L. Johnson, G. J. J. M. van Eys, G. D. Angelini, and S. J. George, “Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 7, pp. 1146–1151, 2001. View at Scopus
  31. R. M. Zwolak, M. C. Adams, and A. W. Clowes, “Kinetics of vein graft hyperplasia: association with tangential stress,” Journal of Vascular Surgery, vol. 5, no. 1, pp. 126–136, 1987. View at Scopus
  32. B. Howden, P. Jablonski, M. Biguzas, et al., “Effect of allopurinol superoxide-dismutase and catalase on renal-transplants in the rat,” Kidney International, vol. 35, no. 2, p. 746, 1989.
  33. J. Y. Jeremy, N. Shukla, S. Muzaffar, A. Handley, and G. D. Angelini, “Reactive oxygen species, vascular disease and cardiovascular surgery,” Current Vascular Pharmacology, vol. 2, no. 3, pp. 229–236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Kirchengast and K. Münter, “Endothelin and restenosis,” Cardiovascular Research, vol. 39, no. 3, pp. 550–555, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Zargham, “Preventing restenosis after angioplasty: a multistage approach,” Clinical Science, vol. 114, no. 3-4, pp. 257–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Honda and P. J. Fitzgerald, “The renaissance of directional coronary atherectomy: a second look from the inside,” The Journal of Invasive Cardiology, vol. 13, no. 11, pp. 748–751, 2001. View at Scopus
  37. S. Mishra, R. M. Wolfram, R. Torguson et al., “Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis,” American Journal of Cardiology, vol. 97, no. 9, pp. 1303–1307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Di Mario, R. Gil, E. Camenzind et al., “Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy,” American Journal of Cardiology, vol. 75, no. 12, pp. 772–777, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Schainfeld, “Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature,” Catheterization and Cardiovascular Interventions, vol. 56, no. 3, pp. 421–431, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. O. F. Bertrand, R. Sipehia, R. Mongrain et al., “Biocompatibility aspects of new stent technology,” Journal of the American College of Cardiology, vol. 32, no. 3, pp. 562–571, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. C. S. Wong, M. B. Leon, and J. J. Popma, “New device angioplasty: the impact on restenosis,” Coronary Artery Disease, vol. 4, no. 3, pp. 243–253, 1993. View at Scopus
  42. G. W. Stone, E. de Marchena, D. Dageforde et al., “Prospective, randomized, multicenter comparison of laser-facilitated balloon angioplasty versus stand-alone balloon angioplasty in patients with obstructive coronary artery disease,” Journal of the American College of Cardiology, vol. 30, no. 7, pp. 1714–1721, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Köster, C. W. Hamm, R. Seabra-Gomes et al., “Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial,” Journal of the American College of Cardiology, vol. 34, no. 1, pp. 25–32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. G. R. Giugliano, M. W. Falcone, D. Mego, et al., “A prospective multicenter registry of laser therapy for degenerated saphenous vein graft stenosis: the COronary graft Results following Atherectomy with Laser (CORAL) trial,” Cardiovascular Revascularization Medicine, vol. 13, no. 2, pp. 84–89, 2012. View at Publisher · View at Google Scholar
  45. P. Zilla, P. Human, M. Wolf et al., “Constrictive external nitinol meshes inhibit vein graft intimal hyperplasia in nonhuman primates,” The Journal of Thoracic and Cardiovascular Surgery, vol. 136, no. 3, pp. 717–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Versaci, A. Gaspardone, F. Tomai, F. Crea, L. Chiariello, and P. A. Gioffrè, “A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery,” The New England Journal of Medicine, vol. 336, no. 12, pp. 817–822, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Escaned, J. Goicolea, F. Alfonso et al., “Propensity and mechanisms of restenosis in different coronary stent designs: complementary value of the analysis of the luminal gain-loss relationship,” Journal of the American College of Cardiology, vol. 34, no. 5, pp. 1490–1497, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. M. A. Bettmann, B. T. Katzen, J. Whisnant et al., “Carotid stenting and angioplasty: a statement for healthcare professionals from the councils on cardiovascular radiology, stroke, cardio-thoracic and vascular surgery, epidemiology and prevention, and clinical cardiology, American Heart Association,” Circulation, vol. 97, no. 1, pp. 121–123, 1998. View at Scopus
  49. R. Virmani, F. Liistro, G. Stankovic et al., “Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans,” Circulation, vol. 106, no. 21, pp. 2649–2651, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Tung, S. Kaul, G. A. Diamond, and P. K. Shah, “Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence,” Annals of Internal Medicine, vol. 144, no. 12, pp. 913–919, 2006. View at Scopus
  51. A. Anzuini, S. Rosanio, V. Legrand et al., “Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience,” Journal of the American College of Cardiology, vol. 31, no. 2, pp. 281–288, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. Ahmed, G. S. Mintz, N. J. Weissman et al., “Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study,” Circulation, vol. 102, no. 1, pp. 7–10, 2000. View at Scopus
  53. B. Reimers, I. Moussa, T. Akiyama et al., “Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis,” Journal of the American College of Cardiology, vol. 30, no. 1, pp. 186–192, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Eltchaninoff, R. Koning, C. Tron, V. Gupta, and A. Cribier, “Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate,” Journal of the American College of Cardiology, vol. 32, no. 4, pp. 980–984, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. G. E. Austin, N. B. Ratliff, J. Hollman, et al., “Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty,” Journal of the American College of Cardiology, vol. 6, no. 2, pp. 369–375, 1985. View at Scopus
  56. K. N. Garratt, D. R. Holmes, M. R. Bell et al., “Restenosis after directional coronary atherectomy: differences between primary atheromatous and restenosis lesions and influence of subintimal tissue resection,” Journal of the American College of Cardiology, vol. 16, no. 7, pp. 1665–1671, 1990. View at Scopus
  57. L. A. Guzman, M. J. Mick, A. M. Arnold, F. Forudi, and P. L. Whitlow, “Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 3, pp. 479–487, 1996. View at Scopus
  58. T. N. Wight and M. J. Merrilees, “Proteoglycans in atherosclerosis and restenosis: key roles for versican,” Circulation Research, vol. 94, no. 9, pp. 1158–1167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. E. R. O'Brien, S. Urieli-Shoval, M. R. Garvin et al., “Replication in restenotic atherectomy tissue,” Atherosclerosis, vol. 152, no. 1, pp. 117–126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Riessen, J. M. Isner, E. Blessing, C. Loushin, S. Nikol, and T. N. Wight, “Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries,” American Journal of Pathology, vol. 144, no. 5, pp. 962–974, 1994. View at Scopus
  61. T. N. Wight, S. Lara, R. Riessen, R. Le Baron, and J. Isner, “Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries,” American Journal of Pathology, vol. 151, no. 4, pp. 963–973, 1997. View at Scopus
  62. T. Ohara, S. Nanto, S. Asada, et al., “Electron-microscopical evaluation of repeat PTCA for restenosis,” Circulation, vol. 80, supplement 2, p. II-65, 1989.
  63. D. E. Johnson, T. Hinohara, M. R. Selmon, L. J. Braden, and J. B. Simpson, “Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study,” Journal of the American College of Cardiology, vol. 15, no. 2, pp. 419–425, 1990. View at Scopus
  64. C. Bauters, T. Meurice, M. Hamon, E. McFadden, J. M. Lablanche, and M. E. Bertrand, “Mechanisms and prevention of restenosis: from experimental models to clinical practice,” Cardiovascular Research, vol. 31, no. 6, pp. 835–846, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Alfonso, P. Rodriguez, P. Phillips et al., “Clinical and angiographic implications of coronary stenting in thrombus-containing lesions,” Journal of the American College of Cardiology, vol. 29, no. 4, pp. 725–733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Pasterkamp, D. P. V. de Kleijn, and C. Borst, “Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications,” Cardiovascular Research, vol. 45, no. 4, pp. 843–852, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. M. R. Ward, G. Pasterkamp, A. C. Yeung, and C. Borst, “Arterial remodeling. Mechanisms and clinical implications,” Circulation, vol. 102, no. 10, pp. 1186–1191, 2000. View at Scopus
  68. B. J. G. L. de Smet, D. de Kleijn, R. Hanemaaijer et al., “Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig,” Circulation, vol. 101, no. 25, pp. 2962–2967, 2000. View at Scopus
  69. S. A. Berceli, Z. Jiang, N. V. Klingman et al., “Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling,” Journal of Vascular Surgery, vol. 39, no. 5, pp. 1084–1090, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. M. P. Anstadt, D. L. Franga, V. Portik-Dobos et al., “Native matrix metalloproteinase characteristics may influence early stenosis of venous versus arterial coronary artery bypass grafting conduits,” Chest, vol. 125, no. 5, pp. 1853–1858, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. A. W. Clowes, M. A. Reidy, and M. M. Clowes, “Mechanisms of stenosis after arterial injury,” Laboratory Investigation, vol. 49, no. 2, pp. 208–215, 1983. View at Scopus
  72. M. J. Post, C. Borst, and R. E. Kuntz, “The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and the hypercholesterolemic Yucatan micropig,” Circulation, vol. 89, no. 6, pp. 2816–2821, 1994. View at Scopus
  73. J. H. O'Keefe, B. D. McCallister, T. M. Bateman, D. L. Kuhnlein, R. W. Ligon, and G. O. Hartzler, “Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty,” Journal of the American College of Cardiology, vol. 19, no. 7, pp. 1597–1600, 1992. View at Scopus
  74. D. P. Faxon, T. E. Spiro, S. Minor et al., “Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial,” Circulation, vol. 90, no. 2, pp. 908–914, 1994. View at Scopus
  75. M. J. Brack, S. Ray, A. Chauhan et al., “The subcutaneous heparin and angioplasty restenosis prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome,” Journal of the American College of Cardiology, vol. 26, no. 4, pp. 947–954, 1995. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Freed, R. D. Safian, W. W. O'Neill, M. Safian, D. Jones, and C. L. Grines, “Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 76, no. 16, pp. 1185–1188, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. P. W. Serruys, J. P. R. Herrman, R. Simon et al., “A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty,” The New England Journal of Medicine, vol. 333, no. 12, pp. 757–763, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Cairns, J. Gill, B. Morton et al., “Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR study,” Circulation, vol. 94, no. 7, pp. 1553–1560, 1996. View at Scopus
  79. J. A. Herd, C. M. Ballantyne, J. A. Farmer et al., “Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]),” American Journal of Cardiology, vol. 80, no. 3, pp. 278–286, 1997. View at Publisher · View at Google Scholar · View at Scopus
  80. J. M. Lablanche, E. P. McFadden, N. Meneveau et al., “Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale,” Circulation, vol. 96, no. 10, pp. 3396–3402, 1997. View at Scopus
  81. L. W. Gimple, H. C. Herrmann, M. Winniford, and E. Mammen, “Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 83, no. 11, pp. 1524–1529, 1999. View at Publisher · View at Google Scholar · View at Scopus
  82. R. S. Kiesz, P. Buszman, J. L. Martin et al., “Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study),” Circulation, vol. 103, no. 1, pp. 26–31, 2001. View at Scopus
  83. J. E. Sousa, M. A. Costa, A. C. Abizaid et al., “Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up,” Circulation, vol. 104, no. 17, pp. 2007–2011, 2001. View at Scopus
  84. M. C. Morice, P. W. Serruys, and J. E. Sousa, “A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization,” The New England Journal of Medicine, vol. 346, no. 23, pp. 1773–1780, 2002.
  85. D. R. Holmes, M. Savage, J. M. Lablanche et al., “Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial,” Circulation, vol. 106, no. 10, pp. 1243–1250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Tamai, K. Katoh, T. Yamaguchi et al., “The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2),” American Heart Journal, vol. 143, no. 3, pp. 506–513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Colombo, J. Drzewiecki, A. Banning et al., “Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions,” Circulation, vol. 108, no. 7, pp. 788–794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Weisz, J. W. Moses, P. S. Teirstein et al., “Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy),” American Journal of Cardiology, vol. 99, no. 8, pp. 1044–1050, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Ylä-Herttuala, J. E. Markkanen, and T. T. Rissanen, “Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials,” Trends in Cardiovascular Medicine, vol. 14, no. 8, pp. 295–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Williams, J. L. Johnson, K. G. S. Carson, and C. L. Jackson, “Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 788–792, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Virmani, A. P. Burke, F. D. Kolodgie, and A. Farb, “Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque,” Journal of Interventional Cardiology, vol. 16, no. 3, pp. 267–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Y. Jeremy and A. C. Thomas, “Animal models for studying neointima formation,” Current Vascular Pharmacology, vol. 8, no. 2, pp. 198–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. A. C. Thomas, “Animal models for studying vein graft failure and therapeutic interventions,” Current Opinion in Pharmacology, vol. 12, no. 2, pp. 121–126, 2012. View at Publisher · View at Google Scholar
  94. J. J. Badimon, A. F. Ortiz, B. Meyer et al., “Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening,” Atherosclerosis, vol. 140, no. 2, pp. 307–314, 1998. View at Publisher · View at Google Scholar · View at Scopus
  95. A. C. Thomas and J. H. Campbell, “Differences in response of rat and rabbit arteries to injury,” Biomedical Research, vol. 11, no. 2, pp. 189–196, 2000.
  96. J. Holm and G. K. Hansson, “Cellular and immunologic features of carotid artery disease in man and experimental animal models,” European Journal of Vascular Surgery, vol. 4, no. 1, pp. 49–55, 1990. View at Scopus
  97. N. F. Worth, C. L. Berry, A. C. Thomas, and J. H. Campbell, “S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits,” Atherosclerosis, vol. 183, no. 1, pp. 65–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. G. J. Murphy, T. W. Johnson, M. H. Chamberlain et al., “Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts,” Cardiovascular Research, vol. 73, no. 3, pp. 607–617, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. A. M. Lincoff, E. J. Topol, and S. G. Ellis, “Local drug delivery for the prevention of restenosis: fact, fancy, and future,” Circulation, vol. 90, no. 4, pp. 2070–2084, 1994. View at Scopus
  100. J. Steffel, F. R. Eberli, T. F. Lüscher, and F. C. Tanner, “Drug-eluting stents—what should be improved?” Annals of Medicine, vol. 40, no. 4, pp. 242–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. B. R. Landzberg, W. H. Frishman, and K. Lerrick, “Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures,” Progress in Cardiovascular Diseases, vol. 39, no. 4, pp. 361–398, 1997. View at Publisher · View at Google Scholar · View at Scopus
  102. D. J. Hayzer, I. M. Lubin, and M. S. Runge, “Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents,” Bioconjugate Chemistry, vol. 2, no. 5, pp. 301–308, 1991. View at Scopus
  103. C. Bode, S. R. Hanson, J. F. Schmedtje et al., “Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting,” Circulation, vol. 95, no. 4, pp. 800–804, 1997. View at Scopus
  104. J. F. Liang, Y. J. Park, H. Song, Y. T. Li, and V. C. M. Yang, “ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs,” Journal of Controlled Release, vol. 72, no. 1–3, pp. 145–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Peter, A. Gupta, T. Nordt, S. Bauer, M. S. Runge, and C. Bode, “Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor Xa-dependent manner,” Journal of Cardiovascular Pharmacology, vol. 42, no. 2, pp. 237–244, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. A. C. Thomas and J. H. Campbell, “Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis,” Atherosclerosis, vol. 176, no. 1, pp. 73–81, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. A. C. Thomas and J. H. Campbell, “Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs,” Journal of Controlled Release, vol. 100, no. 3, pp. 357–377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Daemen, N. Kukreja, P. H. van Twisk et al., “Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry,” American Journal of Cardiology, vol. 101, no. 8, pp. 1105–1111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Silber, A. Colombo, A. P. Banning et al., “Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions,” Circulation, vol. 120, no. 15, pp. 1498–1504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. C. J. McKenna, D. R. Holmes, and R. S. Schwartz, “Novel stents for the prevention of restenosis,” Trends in Cardiovascular Medicine, vol. 7, no. 7, pp. 245–249, 1997. View at Publisher · View at Google Scholar · View at Scopus
  111. M. I. Papafaklis, Y. S. Chatzizisis, K. K. Naka, et al., “Drug-eluting stent restenosis: effect of drug type, release kinetics, hemodynamics and coating strategy,” Pharmacology & Therapeutics, vol. 134, no. 1, pp. 43–53, 2012. View at Publisher · View at Google Scholar
  112. M. Chorny, I. Fishbein, and G. Golomb, “Drug delivery systems for the treatment of restenosis,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 17, no. 3, pp. 249–284, 2000. View at Scopus
  113. S. R. Bailey, “Local drug delivery: current applications,” Progress in Cardiovascular Diseases, vol. 40, no. 2, pp. 183–204, 1997. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Herdeg, K. Göhring-Frischholz, K. K. Haase et al., “Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation,” Circulation, vol. 2, no. 4, pp. 294–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Brieger and E. Topol, “Local drug delivery systems and prevention of restenosis,” Cardiovascular Research, vol. 35, no. 3, pp. 405–413, 1997. View at Publisher · View at Google Scholar · View at Scopus
  116. M. J. Merrilees, B. Beaumont, L. Scott, V. Hermanutz, and P. Fennessy, “Effect of TGF-β1 antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries,” Journal of Vascular Research, vol. 37, no. 1, pp. 50–60, 2000. View at Scopus
  117. M. A. Lovich and E. R. Edelman, “Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11111–11116, 1999. View at Publisher · View at Google Scholar · View at Scopus
  118. E. R. Edelman, D. H. Adams, and M. J. Karnovsky, “Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 10, pp. 3773–3777, 1990. View at Publisher · View at Google Scholar · View at Scopus
  119. J. A. Bingley, I. P. Hayward, J. H. Campbell, and G. R. Campbell, “Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo,” Journal of Vascular Surgery, vol. 28, no. 2, pp. 308–318, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Chaux, X. M. Ruan, M. C. Fishbein et al., “Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation,” The Journal of Thoracic and Cardiovascular Surgery, vol. 115, no. 3, pp. 604–614, 1998. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Rajathurai, S. I. Rizvi, H. Lin, G. D. Angelini, A. C. Newby, and G. J. Murphy, “Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts,” Circulation, vol. 3, no. 2, pp. 157–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. H. M. Nugent, Y. S. Ng, D. White, A. Groothius, G. Kanner, and E. R. Edelman, “Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model,” Journal of Vascular and Interventional Radiology, vol. 20, no. 12, pp. 1617–1624, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. M. J. Merrilees, B. W. Beaumont, K. R. Braun et al., “Neointima formed by arterial smooth muscle cells expressing versican variant V3 is resistant to lipid and macrophage accumulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1309–1316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. S. J. White and A. C. Newby, “Gene therapy for all aspects of vein-graft disease,” Journal of Cardiac Surgery, vol. 17, no. 6, pp. 549–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. A. C. Thomas, M. J. Wyatt, and A. C. Newby, “Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer,” Thrombosis and Haemostasis, vol. 102, no. 1, pp. 145–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. M. J. Underwood, G. Cooper, R. More et al., “Effect of intraluminal application of tissue-type plasminogen activator on the fibrinolytic activity of experimental vein grafts,” Cardiovascular Research, vol. 29, no. 3, pp. 422–427, 1995. View at Publisher · View at Google Scholar · View at Scopus
  127. S. J. George, C. T. Lloyd, G. D. Angelini, A. C. Newby, and A. H. Baker, “Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3,” Circulation, vol. 101, no. 3, pp. 296–304, 2000. View at Scopus
  128. P. Ehrlich, “Address in pathology, ‘On Chemotherapy’: delivered before the Seventeenth International Congress of Medicine,” British Medical Journal, vol. 2, no. 2746, pp. 353–359, 1913. View at Publisher · View at Google Scholar
  129. C. Bode, M. Hudelmayer, P. Mehwald et al., “Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin,” Circulation, vol. 90, no. 4, pp. 1956–1963, 1994. View at Scopus
  130. A. C. Thomas and J. H. Campbell, “Timecourse of fibrin deposition and removal after arterial injury,” Thrombosis Research, vol. 109, no. 1, pp. 65–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. Z. Gu, B. E. Rolfe, Z. P. Xu, et al., “Antibody-targeted drug delivery to injured arteries using layered double hydroxide nanoparticles,” Advanced Healthcare Materials, vol. 1, no. 5, pp. 669–673, 2012. View at Publisher · View at Google Scholar
  132. B. J. Lestini, S. M. Sagnella, Z. Xu et al., “Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery,” Journal of Controlled Release, vol. 78, no. 1–3, pp. 235–247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. G. M. Lanza, X. Yu, P. M. Winter et al., “Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis,” Circulation, vol. 106, no. 22, pp. 2842–2847, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza, “Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 3, pp. 435–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. T. Cyrus, H. Zhang, J. S. Allen et al., “Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 820–826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. R. V. J. Chari, “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy,” Advanced Drug Delivery Reviews, vol. 31, no. 1-2, pp. 89–104, 1998. View at Publisher · View at Google Scholar · View at Scopus
  137. M. P. Turunen, H. L. Puhakka, J. K. Koponen et al., “Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer,” Molecular Therapy, vol. 6, no. 3, pp. 306–312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. T. T. Rissanen and S. Ylä-Herttuala, “Current status of cardiovascular gene therapy,” Molecular Therapy, vol. 15, no. 7, pp. 1233–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. H. E. von der Leyen, A. Mugge, C. Hanefeld, et al., “A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension),” Human Gene Therapy, vol. 22, no. 8, pp. 951–958, 2011. View at Publisher · View at Google Scholar
  140. S. Yla-Herttuala, “In vivo and ex vivo strategies for vascular gene therapy,” Journal of Submicroscopic Cytology and Pathology, vol. 32, p. 481, 2000.
  141. J. Rutanen, J. Markkanen, and S. Ylä-Herttuala, “Gene therapy for restenosis current status,” Drugs, vol. 62, no. 11, pp. 1575–1585, 2002. View at Scopus
  142. S. Banai, M. Chorny, S. D. Gertz et al., “Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries,” Biomaterials, vol. 26, no. 4, pp. 451–461, 2005.
  143. H. D. Danenberg, I. Fishbein, J. Gao et al., “Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits,” Circulation, vol. 106, no. 5, pp. 599–605, 2002. View at Publisher · View at Google Scholar · View at Scopus
  144. H. D. Danenberg, G. Golomb, A. Groothuis et al., “Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits,” Circulation, vol. 108, no. 22, pp. 2798–2804, 2003. View at Publisher · View at Google Scholar · View at Scopus
  145. E. Afergan, M. Ben-David, H. Epstein et al., “Liposomal simvastatin attenuates neointimal hyperplasia in rats,” The AAPS Journal, vol. 12, no. 2, pp. 181–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. B. C. Berk, J. B. Gordon, and R. W. Alexander, “Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty,” Journal of the American College of Cardiology, vol. 17, no. 6, pp. 111B–117B, 1991. View at Scopus
  147. M. S. Weinberg, “The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies,” Rhode Island Medicine, vol. 78, no. 3, pp. 78–81, 1995. View at Scopus
  148. M. Hamon, E. Lécluse, J. P. Monassier, G. Grollier, and J. C. Potier, “Pharmacological approaches to the prevention of restenosis after coronary angioplasty,” Drugs and Aging, vol. 13, no. 4, pp. 291–301, 1998. View at Publisher · View at Google Scholar · View at Scopus
  149. P. J. Casterella and P. S. Teirstein, “Prevention of coronary restenosis,” Cardiology in Review, vol. 7, no. 4, pp. 219–231, 1999. View at Scopus
  150. R. Rabbani and E. J. Topol, “Strategies to achieve coronary arterial plaque stabilization,” Cardiovascular Research, vol. 41, no. 2, pp. 402–417, 1999. View at Publisher · View at Google Scholar · View at Scopus
  151. A. W. Chan, D. P. Chew, and A. M. Lincoff, “Update on pharmacology for restenosis,” Current Interventional Cardiology Reports, vol. 3, no. 2, pp. 149–155, 2001.
  152. R. Voisard, U. Seitzer, R. Baur et al., “A prescreening system for potential antiproliferative agents—implications for local treatment strategies of postangioplasty restenosis,” International Journal of Cardiology, vol. 51, no. 1, pp. 15–28, 1995. View at Publisher · View at Google Scholar · View at Scopus
  153. Y. K. Ahn, M. H. Jeong, J. W. Kim, et al., “Preventive effects of the heparin-coated stent on restenosis in the porcine model,” Catheterization and Cardiovascular Interventions, vol. 48, no. 3, pp. 324–330, 1999.
  154. S. G. Ellis, G. S. Roubin, J. Wilentz, J. S. Douglas, and S. B. King, “Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty,” American Heart Journal, vol. 117, no. 4, pp. 777–782, 1989. View at Scopus
  155. P. S. K. Paty, R. C. Darling, P. B. Kreienberg et al., “The use of low-dose heparin is safe in carotid endarterectomy and avoids the use of protamine sulfate,” Cardiovascular Surgery, vol. 7, no. 1, pp. 39–43, 1999. View at Publisher · View at Google Scholar · View at Scopus
  156. D. A. Cox, P. G. Anderson, G. S. Roubin, C. Y. Chou, S. K. Agrawal, and J. B. Cavender, “Effect of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries,” Coronary Artery Disease, vol. 3, no. 3, pp. 237–248, 1992. View at Scopus
  157. Y. Matsumoto, H. Shimokawa, K. Morishige, Y. Eto, and A. Takeshita, “Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries,” Journal of Cardiovascular Pharmacology, vol. 39, no. 4, pp. 513–522, 2002. View at Publisher · View at Google Scholar · View at Scopus
  158. M. C. M. Vrolix, V. M. Legrand, J. H. C. Reiber et al., “Heparin-coated Wiktor stents in human coronary arteries (MENTOR Trial),” American Journal of Cardiology, vol. 86, no. 4, pp. 385–389, 2000. View at Publisher · View at Google Scholar · View at Scopus
  159. P. W. Serruys, B. van Hout, H. Bonnier et al., “Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II),” The Lancet, vol. 352, no. 9129, pp. 673–681, 1998. View at Scopus
  160. J. Wöhrle, E. Al-Khayer, U. Grötzinger et al., “Comparison of the heparin coated vs the uncoated Jostent—no influence on restenosis or clinical outcome,” European Heart Journal, vol. 22, no. 19, pp. 1808–1816, 2001. View at Publisher · View at Google Scholar · View at Scopus
  161. J. W. Currier, T. K. Pow, C. C. Haudenschild, A. C. Minihan, and D. P. Faxon, “Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit,” Journal of the American College of Cardiology, vol. 17, no. 6, pp. 118B–125B, 1991. View at Scopus
  162. M. Oberhoff, C. Herdeg, A. Baumbach, et al., “Time course of smooth muscle cell proliferation after local drug delivery of low-molecular-weight heparin using a porous balloon catheter,” Catheterization and Cardiovascular Diagnosis, vol. 41, pp. 268–274, 1997.
  163. M. Oberhoff, S. Novak, C. Herdeg et al., “Local and systemic delivery of low molecular weight heparin stimulates the reendothelialization after balloon angioplasty,” Cardiovascular Research, vol. 38, no. 3, pp. 751–762, 1998. View at Publisher · View at Google Scholar · View at Scopus
  164. N. Meneveau, F. Schiele, G. Grollier et al., “Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study,” European Heart Journal, vol. 21, no. 21, pp. 1767–1775, 2000. View at Scopus
  165. Z. Gu, B. E. Rolfe, Z. P. Xu, A. C. Thomas, J. H. Campbell, and G. Q. M. Lu, “Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells,” Biomaterials, vol. 31, no. 20, pp. 5455–5462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. Z. Gu, B. E. Rolfe, A. C. Thomas, J. H. Campbell, G. Q. M. Lu, and Z. P. Xu, “Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells,” Biomaterials, vol. 32, no. 29, pp. 7234–7240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. M. Heras, J. H. Chesebro, W. J. Penny, K. R. Bailey, L. Badimon, and V. Fuster, “Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor,” Circulation, vol. 79, no. 3, pp. 657–665, 1989. View at Scopus
  168. C. Gerdes, V. Faber-Steinfeld, O. Yalkinoglu, and S. Wohlfeil, “Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 10, pp. 1306–1311, 1996. View at Scopus
  169. M. Ragosta, W. L. Barry, L. W. Gimple et al., “Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits,” Circulation, vol. 93, no. 6, pp. 1194–1200, 1996. View at Scopus
  170. S. D. Gertz, J. T. Fallon, R. Gallo et al., “Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries,” Circulation, vol. 98, no. 6, pp. 580–587, 1998. View at Scopus
  171. E. Alt, I. Haehnel, C. Beilharz et al., “Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost,” Circulation, vol. 101, no. 12, pp. 1453–1458, 2000. View at Scopus
  172. P. A. Lapchak and D. M. Araujo, “Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents,” CNS Drugs, vol. 15, no. 11, pp. 819–829, 2001. View at Scopus
  173. S. Bjorkerud, “Impaired fibrinolysis-inducing capacity for postinjury phenotype of cultivated human arterial and human atherosclerotic intimal smooth muscle cells,” Circulation Research, vol. 62, no. 5, pp. 1011–1018, 1988. View at Scopus
  174. T. Padro, J. J. Emeis, M. Steins, K. W. Schmid, and J. Kienast, “Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 7, pp. 893–902, 1995. View at Scopus
  175. P. Glas-Greenwalt, B. C. Dalton, and T. Astrup, “Localization of tissue plasminogen activator in relation to morphologic changes in human saphenous veins used as coronary artery bypass autografts,” Annals of Surgery, vol. 181, no. 4, pp. 431–441, 1975. View at Scopus
  176. P. Kauhanen, V. Sirén, O. Carpén, A. Vaheri, M. Lepäntalo, and R. Lassila, “Plasminogen activator inhibitor-1 neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure,” Circulation, vol. 96, no. 6, pp. 1783–1789, 1997. View at Scopus
  177. J. V. Manchio, J. Gu, L. Romar et al., “Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery,” Annals of Thoracic Surgery, vol. 79, no. 6, pp. 1991–1998, 2005. View at Publisher · View at Google Scholar · View at Scopus
  178. P. R. Hilfiker, J. M. Waugh, J. J. Li-Hawkins et al., “Enhancement of neointima formation with tissue-type plasminogen activator,” Journal of Vascular Surgery, vol. 33, no. 4, pp. 821–828, 2001. View at Publisher · View at Google Scholar · View at Scopus
  179. E. J. Topol, T. V. Byzova, and E. F. Plow, “Platelet GPIIb-IIIa blockers,” The Lancet, vol. 353, no. 9148, pp. 227–231, 1999. View at Publisher · View at Google Scholar · View at Scopus
  180. S. A. Mousa, R. Kapil, and D. X. Mu, “Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 10, pp. 2535–2541, 1999. View at Scopus
  181. W. Volker and V. Faber, “Aspirin reduces the growth of medial and neointimal thickenings in balloon-injured rat carotid arteries,” Stroke, vol. 21, no. 12, pp. IV44–IV45, 1990. View at Scopus
  182. A. J. Coukell and A. Markham, “Clopidogrel,” Drugs, vol. 54, no. 5, pp. 745–750, 1997. View at Scopus
  183. A. Schömig, F. J. Neumann, A. Kastrati et al., “A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents,” The New England Journal of Medicine, vol. 334, no. 17, pp. 1084–1089, 1996. View at Publisher · View at Google Scholar · View at Scopus
  184. B. S. Coller, “The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy,” European Heart Journal, vol. 16, pp. L11–L15, 1995. View at Scopus
  185. R. R. Azar, R. G. McKay, P. D. Thompson et al., “Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes,” Journal of the American College of Cardiology, vol. 32, no. 7, pp. 1996–2002, 1998. View at Publisher · View at Google Scholar · View at Scopus
  186. D. Hasdai, C. S. Rihal, M. R. Bell et al., “Abciximab administration and outcome after intracoronary stent implantation,” American Journal of Cardiology, vol. 82, no. 6, pp. 705–709, 1998. View at Scopus
  187. G. W. Barsness, C. Buller, E. M. Ohman et al., “Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts,” American Heart Journal, vol. 139, no. 5, pp. 824–829, 2000. View at Scopus
  188. Y. J. Hong, M. H. Jeong, S. R. Lee , et al., “Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model,” Journal of Korean Medical Science, vol. 22, no. 5, pp. 802–809, 2007. View at Scopus
  189. A. J. Marcus, L. B. Safier, M. J. Broekman et al., “Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions,” Thrombosis and Haemostasis, vol. 74, no. 1, pp. 213–217, 1995. View at Scopus
  190. C. Timmermans, M. Vrolix, J. Vanhaecke et al., “Ridogrel in the setting of percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 68, no. 5, pp. 463–466, 1991. View at Publisher · View at Google Scholar · View at Scopus
  191. Y. Yabe, K. Okamoto, H. Oosawa, et al., “Does a thromboxane A2 synthetase inhibitor prevent restenosis after PTCA?” Circulation, vol. 80, no. 4, p. II260, 1989.
  192. J. T. Willerson, S. K. Yao, J. McNatt et al., “Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 23, pp. 10624–10628, 1991. View at Scopus
  193. H. V. Anderson, J. McNatt, F. J. Clubb et al., “Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries,” Circulation, vol. 104, no. 19, pp. 2331–2337, 2001. View at Scopus
  194. J. M. van Lierde, M. C. Vrolix, I. K. de Scheerer, et al., “Feasibility of transient delivery of ridogrel via microporous balloon technique in normal canine arteries,” Circulation, vol. 84, p. II296, 1991.
  195. Y. Numaguchi, K. Okumura, M. Harada et al., “Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries,” Cardiovascular Research, vol. 61, no. 1, pp. 177–185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  196. N. Kohda, T. Tani, S. Nakayama et al., “Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery,” Thrombosis Research, vol. 96, no. 4, pp. 261–268, 1999. View at Publisher · View at Google Scholar · View at Scopus
  197. E. Tsuchikane, T. Suzuki, O. Katoh, and T. Suzuki, “Examination of anti-intima hyperplastic effect on cilostazol-eluting stent in a porcine model,” Journal of Invasive Cardiology, vol. 19, no. 3, pp. 109–112, 2007. View at Scopus
  198. S. Take, M. Matsutani, H. Ueda et al., “Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 79, no. 8, pp. 1097–1099, 1997. View at Publisher · View at Google Scholar · View at Scopus
  199. K. Kozuma, K. Hara, M. Yamasaki et al., “Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation,” American Heart Journal, vol. 141, no. 1, pp. 124–130, 2001. View at Publisher · View at Google Scholar · View at Scopus
  200. M. Sekiya, J. Funada, K. Watanabe, M. Miyagawa, and H. Akutsu, “Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis,” American Journal of Cardiology, vol. 82, no. 2, pp. 144–147, 1998. View at Publisher · View at Google Scholar · View at Scopus
  201. N. Ishizaka, J. Taguchi, Y. Kimura et al., “Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery,” Atherosclerosis, vol. 142, no. 1, pp. 41–46, 1999. View at Publisher · View at Google Scholar · View at Scopus
  202. G. A. Higgs, K. G. Mugridge, S. Moncada, and J. R. Vane, “Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 9, pp. 2890–2892, 1984. View at Scopus
  203. I. de Meyer, W. Martinet, D. M. Schrijvers, et al., “Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques,” Basic Research in Cardiology, vol. 107, p. 269, 2012. View at Publisher · View at Google Scholar
  204. A. E. Villa, L. A. Guzman, W. Chen, G. Golomb, R. J. Levy, and E. J. Topol, “Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty,” The Journal of Clinical Investigation, vol. 93, no. 3, pp. 1243–1249, 1994. View at Scopus
  205. T. Suzuki, G. Kopia, S. I. Hayashi et al., “Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model,” Circulation, vol. 104, no. 10, pp. 1188–1193, 2001. View at Scopus
  206. A. König, M. Leibig, J. Rieber et al., “Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis,” American Heart Journal, vol. 153, no. 6, pp. 979.e1–979.e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  207. H. Epstein, V. Berger, I. Levi et al., “Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats,” Journal of Controlled Release, vol. 117, no. 3, pp. 322–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  208. H. Kusama, S. Kikuchi, S. Tazawa et al., “Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21 waf1,” Atherosclerosis, vol. 143, no. 2, pp. 307–313, 1999. View at Publisher · View at Google Scholar · View at Scopus
  209. A. Saiura, M. Sata, Y. Hirata, R. Nagai, and M. Makuuchi, “Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation,” European Journal of Pharmacology, vol. 433, no. 2-3, pp. 163–168, 2001. View at Publisher · View at Google Scholar · View at Scopus
  210. M. R. Ward, A. Agrotis, P. Kanellakis, J. Hall, G. Jennings, and A. Bobik, “Tranilast prevents activation of transforming growth factor-β system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 6, pp. 940–948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  211. K. Kosuga, H. Tamai, K. Ueda et al., “Effectiveness of tranilast on restenosis after directional coronary atherectomy,” American Heart Journal, vol. 134, no. 4, pp. 712–718, 1997. View at Publisher · View at Google Scholar · View at Scopus
  212. L. Denes, L. Entz, and V. Jancsik, “Restenosis and therapy,” International Journal of Vascular Medicine, vol. 2012, Article ID 406236, 9 pages, 2012.
  213. J. Saltis, A. C. Thomas, A. Agrotis, J. H. Campbell, G. R. Campbell, and A. Bobik, “Expression of growth factor receptors on arterial smooth muscle cells. Dependency on cell phenotype and serum factors,” Atherosclerosis, vol. 118, no. 1, pp. 77–87, 1995. View at Publisher · View at Google Scholar · View at Scopus
  214. H. Matsuno, J. M. Stassen, M. F. Hoylaerts, J. Vermylen, and H. Deckmyn, “Fast and reproducible vascular neointima formation in the hamster carotid artery: effects of trapidil and captopril,” Thrombosis and Haemostasis, vol. 74, no. 6, pp. 1591–1596, 1995. View at Scopus
  215. M. W. Liu, G. S. Roubin, K. A. Robinson et al., “Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit,” Circulation, vol. 81, no. 3, pp. 1089–1093, 1990. View at Scopus
  216. K. Zacharowski, D. Schneidmüller, W. Ibe et al., “Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model,” British Journal of Pharmacology, vol. 129, no. 3, pp. 566–572, 2000. View at Scopus
  217. S. Okamoto, M. Inden, M. Setsuda, T. Konishi, and T. Nakano, “Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing stenosis after percutaneous transluminal coronary angioplasty,” American Heart Journal, vol. 123, no. 6, pp. 1439–1444, 1992. View at Publisher · View at Google Scholar · View at Scopus
  218. D. X. Sun, Z. Liu, X. D. Tan, et al., “Nanoparticle-mediated local delivery of an antisense TGFβ1 construct inhibits intimal hyperplasia in autogenous vein grafts in rats,” PLoS ONE, vol. 7, no. 7, Article ID e41857, 2012.
  219. E. Stringa, V. Knäuper, G. Murphy, and J. Gavrilovic, “Collagen degradation and platelet-derived growth factor stimulate the migration of vascular smooth muscle cells,” Journal of Cell Science, vol. 113, no. 11, pp. 2055–2064, 2000. View at Scopus
  220. I. Fishbein, J. Waltenberger, S. Banai et al., “Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 667–676, 2000. View at Scopus
  221. S. Banai, S. D. Gertz, L. Gavish et al., “Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries,” Cardiovascular Research, vol. 64, no. 1, pp. 165–171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  222. E. D. Santoian, J. E. Schneider, M. B. Gravanis et al., “Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries,” Circulation, vol. 88, no. 1, pp. 11–14, 1993. View at Scopus
  223. O. H. Kwok, W. H. Chow, T. C. Law et al., “First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study,” Catheterization and Cardiovascular Interventions, vol. 66, no. 4, pp. 541–546, 2005. View at Publisher · View at Google Scholar · View at Scopus
  224. J. Taguchi, J. Abe, H. Okazaki et al., “Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application,” Biochemical and Biophysical Research Communications, vol. 196, no. 2, pp. 969–974, 1993. View at Publisher · View at Google Scholar · View at Scopus
  225. M. Pretorius, L. J. Murphey, J. A. McFarlane, D. E. Vaughan, and N. J. Brown, “Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass,” Circulation, vol. 108, no. 25, pp. 3079–3083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  226. N. Beohar, J. D. Flaherty, C. J. Davidson et al., “Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model,” Circulation, vol. 109, no. 1, pp. 108–113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  227. T. N. Wight, “The extracellular matrix and atherosclerosis,” Current Opinion in Lipidology, vol. 6, no. 5, pp. 326–334, 1995. View at Scopus
  228. J. L. Johnson, L. Devel, B. Czarny et al., “A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 528–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  229. D. W. M. Muller, S. G. Ellis, and E. J. Topol, “Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions,” Journal of the American College of Cardiology, vol. 17, no. 6, pp. 126B–131B, 1991. View at Scopus
  230. D. Baruch, B. Bahnak, J. P. Girma, and D. Meyer, “Von Willebrand factor and platelet function,” Bailliere's Clinical Haematology, vol. 2, no. 3, pp. 627–672, 1989. View at Scopus
  231. D. P. Faxon and J. W. Currier, “Prevention of post-PTCA restenosis,” Annals of the New York Academy of Sciences, vol. 748, pp. 419–428, 1995. View at Scopus
  232. I. Gradus-Pizlo, R. L. Wilensky, K. L. March et al., “Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery,” Journal of the American College of Cardiology, vol. 26, no. 6, pp. 1549–1557, 1995. View at Publisher · View at Google Scholar · View at Scopus
  233. C. Herdeg, M. Oberhoff, and K. R. Karsch, “Antiproliferative stent coatings: taxol and related compounds,” Seminars in Interventional Cardiology, vol. 3, no. 3-4, pp. 197–199, 1998. View at Scopus
  234. C. W. Hwang, D. Wu, and E. R. Edelman, “Physiological transport forces govern drug distribution for stent-based delivery,” Circulation, vol. 104, no. 5, pp. 600–605, 2001. View at Scopus
  235. D. E. Drachman, E. R. Edelman, P. Seifert et al., “Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months,” Journal of the American College of Cardiology, vol. 36, no. 7, pp. 2325–2332, 2000. View at Publisher · View at Google Scholar · View at Scopus
  236. A. Farb, P. F. Heller, S. Shroff et al., “Pathological analysis of local delivery of paclitaxel via a polymer-coated stent,” Circulation, vol. 104, no. 4, pp. 473–479, 2001. View at Scopus
  237. P. E. Signore, L. S. Machan, J. K. Jackson et al., “Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries,” Journal of Vascular and Interventional Radiology, vol. 12, no. 1, pp. 79–88, 2001. View at Scopus
  238. B. Kelly, M. Melhem, J. Zhang et al., “Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2425–2431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  239. J. M. Chan, L. Zhang, R. Tong et al., “Spatiotemporal controlled delivery of nanoparticles to injured vasculature,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 5, pp. 2213–2218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  240. F. Liistro, G. Stankovic, C. Di Mario et al., “First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome,” Circulation, vol. 105, no. 16, pp. 1883–1886, 2002. View at Publisher · View at Google Scholar · View at Scopus
  241. K. Tanabe, P. W. Serruys, E. Grube et al., “TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation,” Circulation, vol. 107, no. 4, pp. 559–564, 2003. View at Publisher · View at Google Scholar · View at Scopus
  242. O. A. Mendiz, W. H. Ahmed, C. M. Fava, et al., “Clinical outcome after saphenous vein stenting with Taxus Liberte Stent: results from the OLYMPIA registry (TAXUS Liberte Postapproval Global Program),” Angiology, vol. 63, no. 8, pp. 574–578, 2012.
  243. S. H. Duda, T. C. Poerner, B. Wiesinger et al., “Drug-eluting stents: potential applications for peripheral arterial occlusive disease,” Journal of Vascular and Interventional Radiology, vol. 14, no. 3, pp. 291–301, 2003. View at Scopus
  244. I. Iakovou, T. Schmidt, E. Bonizzoni et al., “Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents,” Journal of the American Medical Association, vol. 293, no. 17, pp. 2126–2130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  245. M. Joner, A. V. Finn, A. Farb et al., “Pathology of drug-eluting stents in humans—delayed healing and late thrombotic risk,” Journal of the American College of Cardiology, vol. 48, no. 1, pp. 193–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  246. M. Poon, S. O. Marx, R. Gallo, J. J. Badimon, M. B. Taubman, and A. R. Marks, “Rapamycin inhibits vascular smooth muscle cell migration,” The Journal of Clinical Investigation, vol. 98, no. 10, pp. 2277–2283, 1996. View at Scopus
  247. P. J. Mohacsi, D. Tuller, B. Hulliger, and P. L. J. Wijngaard, “Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor,” Journal of Heart and Lung Transplantation, vol. 16, no. 5, pp. 484–492, 1997. View at Scopus
  248. S. N. Sehgal, “Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression,” Clinical Biochemistry, vol. 31, no. 5, pp. 335–340, 1998. View at Publisher · View at Google Scholar · View at Scopus
  249. C. R. Gregory, P. Huie, M. E. Billingham, and R. E. Morris, “Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine responses in injured vessels,” Transplantation, vol. 55, no. 6, pp. 1409–1418, 1993. View at Scopus
  250. G. J. Murphy and M. L. Nicholson, “Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy,” The Journal of Thoracic and Cardiovascular Surgery, vol. 126, no. 6, pp. 2058–2064, 2003. View at Publisher · View at Google Scholar · View at Scopus
  251. S. E. Burke, N. L. Lubbers, Y. W. Chen et al., “Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin,” Journal of Cardiovascular Pharmacology, vol. 33, no. 6, pp. 829–835, 1999. View at Publisher · View at Google Scholar · View at Scopus
  252. B. D. Klugherz, G. Llanos, W. Lieuallen et al., “Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent,” Coronary Artery Disease, vol. 13, no. 3, pp. 183–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  253. H. L. Chen, K. Liu, X. Y. Meng, X. D. Wen, and Q. S. You, “Local application of rapamycin inhibits vein graft restenosis in rabbits,” Transplantation Proceedings, vol. 43, no. 5, pp. 2017–2021, 2011. View at Publisher · View at Google Scholar · View at Scopus
  254. T. Schachner, Y. Zou, A. Oberhuber et al., “Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts,” Annals of Thoracic Surgery, vol. 77, no. 5, pp. 1580–1585, 2004. View at Publisher · View at Google Scholar · View at Scopus
  255. J. A. S. Muldowney, J. R. Stringham, S. E. Levy et al., “Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 400–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  256. O. Massoud and R. H. Wiesner, “The use of sirolimus should be restricted in liver transplantation,” Journal of Hepatology, vol. 56, no. 1, pp. 288–290, 2012. View at Publisher · View at Google Scholar
  257. R. Virmani, G. Guagliumi, A. Farb et al., “Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?” Circulation, vol. 109, no. 6, pp. 701–705, 2004. View at Publisher · View at Google Scholar · View at Scopus
  258. P. Vermeersch, P. Agostoni, S. Verheye et al., “Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial,” Journal of the American College of Cardiology, vol. 50, no. 3, pp. 261–267, 2007. View at Publisher · View at Google Scholar · View at Scopus
  259. M. Igarashi, Y. Takeda, S. Mori et al., “Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth,” British Journal of Pharmacology, vol. 120, no. 6, pp. 1172–1178, 1997. View at Publisher · View at Google Scholar · View at Scopus
  260. M. R. Soma, E. Donetti, C. Parolini et al., “HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits,” Arteriosclerosis and Thrombosis, vol. 13, no. 4, pp. 571–578, 1993. View at Scopus
  261. J. Alfon, J. F. Guasch, M. Berrozpe, and L. Badimon, “Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors,” Atherosclerosis, vol. 145, no. 2, pp. 325–331, 1999. View at Publisher · View at Google Scholar · View at Scopus
  262. J. R. Sindermann, L. Fan, K. A. Weigel et al., “Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture,” Atherosclerosis, vol. 150, no. 2, pp. 331–341, 2000. View at Publisher · View at Google Scholar · View at Scopus
  263. Z. Luan, A. J. Chase, and A. C. Newby, “Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 769–775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  264. P. Libby and M. Aikawa, “Effects of statins in reducing thrombotic risk and modulating plaque vulnerability,” Clinical Cardiology, vol. 26, no. 1, pp. I11–I14, 2003. View at Scopus
  265. A. Yilmaz, C. Reiss, O. Tantawi et al., “HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis,” Atherosclerosis, vol. 172, no. 1, pp. 85–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  266. T. A. Miettinen, K. Pyörälä, A. G. Olsson et al., “Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S),” Circulation, vol. 96, no. 12, pp. 4211–4218, 1997. View at Scopus
  267. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels,” The New England Journal of Medicine, vol. 339, pp. 1349–1357, 1998. View at Publisher · View at Google Scholar
  268. B. Cucchiara and S. E. Kasner, “Use of statins in CNS disorders,” Journal of the Neurological Sciences, vol. 187, no. 1-2, pp. 81–89, 2001. View at Publisher · View at Google Scholar · View at Scopus
  269. W. S. Weintraub, S. J. Boccuzzi, J. L. Klein et al., “Lack of effect of lovastatin on restenosis after coronary angioplasty,” The New England Journal of Medicine, vol. 331, no. 20, pp. 1331–1337, 1994. View at Publisher · View at Google Scholar · View at Scopus
  270. M. E. Bertrand, E. P. McFadden, J. C. Fruchart et al., “Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty,” Journal of the American College of Cardiology, vol. 30, no. 4, pp. 863–869, 1997. View at Publisher · View at Google Scholar · View at Scopus
  271. A. Kleemann, S. Eckert, A. von Eckardstein et al., “Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT),” European Heart Journal, vol. 20, no. 19, pp. 1393–1406, 1999. View at Publisher · View at Google Scholar · View at Scopus
  272. D. H. Walter, V. Schächinger, M. Elsner, S. Mach, W. Auch-Schwelk, and A. M. Zeiher, “Effect of statin therapy on restenosis after coronary stent implantation,” American Journal of Cardiology, vol. 85, no. 8, pp. 962–968, 2000. View at Publisher · View at Google Scholar · View at Scopus
  273. H. C. Jeong, Y. Ahn, Y. J. Hong, et al., “Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein,” International Journal of Cardiology. In press.
  274. K. Miyauchi, T. Kasai, T. Yokayama et al., “Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model,” Circulation Journal, vol. 72, no. 5, pp. 832–838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  275. M. N. Diaz, B. Frei, J. A. Vita, and J. F. Keaney, “Antioxidants and atherosclerotic heart disease,” The New England Journal of Medicine, vol. 337, no. 6, pp. 408–416, 1997. View at Publisher · View at Google Scholar · View at Scopus
  276. Heart Protection Study Collaborative Group, “MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 23–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  277. E. R. Edelman, “Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late,” Circulation, vol. 97, no. 5, pp. 416–420, 1998. View at Scopus
  278. J. C. Tardif, G. Côté, J. Lespérance et al., “Probucol and multivitamins in the prevention of restenosis after coronary angioplasty,” The New England Journal of Medicine, vol. 337, no. 6, pp. 365–372, 1997. View at Publisher · View at Google Scholar · View at Scopus
  279. T. Kita, Y. Nagano, M. Yokode et al., “Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 16, pp. 5928–5931, 1987. View at Scopus
  280. G. Côté, J. C. Tardif, J. Lespérance et al., “Effects of probucol on vascular remodeling after coronary angioplasty,” Circulation, vol. 99, no. 1, pp. 30–35, 1999. View at Scopus
  281. H. Yokoi, H. Daida, Y. Kuwabara et al., “Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial,” Journal of the American College of Cardiology, vol. 30, no. 4, pp. 855–862, 1997. View at Publisher · View at Google Scholar · View at Scopus
  282. D. L. Tribble, “Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and β-carotene,” Circulation, vol. 99, no. 4, pp. 591–595, 1999. View at Scopus
  283. J. J. Kleinedler, J. D. Foley, E. A. Orchard, et al., “Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization,” Journal of Controlled Release, vol. 159, no. 1, pp. 27–33, 2012. View at Publisher · View at Google Scholar
  284. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at Scopus
  285. N. Shukla, G. D. Angelini, R. Ascione, S. Talpahewa, R. Capoun, and J. Y. Jeremy, “Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure,” Annals of Thoracic Surgery, vol. 75, no. 5, pp. 1437–1442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  286. K. Mavromatis, T. Fukai, M. Tate, N. Chesler, D. N. Ku, and Z. S. Galis, “Early effects of arterial hemodynamic conditions on human saphenous veins perfused ex vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 8, pp. 1889–1895, 2000. View at Scopus
  287. J. H. Bräsen, O. Leppänen, M. Inkala et al., “extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta,” Journal of the American College of Cardiology, vol. 50, no. 23, pp. 2249–2253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  288. D. Wiedemann, A. Kocher, N. Bonaros, et al., “Perivascular administration of drugs and genes as a means of reducing vein graft failure,” Current Opinion in Pharmacology, vol. 12, no. 2, pp. 203–216, 2012. View at Publisher · View at Google Scholar
  289. E. Allaire and A. W. Clowes, “Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response,” Annals of Thoracic Surgery, vol. 63, no. 2, pp. 582–591, 1997. View at Publisher · View at Google Scholar · View at Scopus